**Core Concept**
Small cell lung cancer (SCLC) is a highly aggressive and malignant subtype of lung cancer, characterized by rapid growth and early metastasis. It is often associated with paraneoplastic syndromes and is typically linked to cigarette smoking.

**Why the Correct Answer is Right**
SCLC is a neuroendocrine tumor that originates from the neuroendocrine cells of the lung. It is known for its rapid growth and early metastasis, often presenting with distant metastases at the time of diagnosis. The cells of SCLC express neuroendocrine markers such as chromogranin A and synaptophysin, and are often positive for TTF-1 (thyroid transcription factor-1), a marker that helps distinguish SCLC from non-small cell lung cancer (NSCLC). The high mitotic rate and rapid proliferation of SCLC cells contribute to its aggressive behavior and poor prognosis.

**Why Each Wrong Option is Incorrect**
**Option A:** Not a characteristic of small cell lung cancer.
Small cell lung cancer is a distinct subtype of lung cancer with its own unique clinical, pathological, and molecular features, and is not simply a variant of non-small cell lung cancer.

**Option B:** Not a typical presentation of small cell lung cancer.
While SCLC can present with a variety of symptoms, including cough, chest pain, and weight loss, it is often associated with paraneoplastic syndromes such as syndrome of inappropriate antidiuretic hormone secretion (SIADH), Eaton-Lambert syndrome, and Cushing's syndrome.

**Option C:** Not a hallmark of small cell lung cancer.
While SCLC can be associated with a range of molecular alterations, including mutations in the TP53 gene, it is not typically characterized by the presence of EGFR mutations, which are more commonly found in NSCLC.

**Option D:** Not a defining feature of small cell lung cancer.
While SCLC can be treated with a range of modalities, including chemotherapy, radiation therapy, and surgery, its treatment is not typically based on the presence or absence of a specific biomarker.

**Clinical Pearl / High-Yield Fact**
SCLC is often associated with a poor prognosis due to its rapid growth and early metastasis, and is typically treated with a combination of chemotherapy and radiation therapy. The presence of paraneoplastic syndromes can also impact treatment and prognosis.

**Correct Answer:** Not provided